New drug combo tested for ovarian cancer: will it work?

NCT ID NCT07402915

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to understand drug interactions, not to treat the cancer directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AZD5335 (antibody drug conjugate) and itraconazole
What this could lead to
If successful, this could help determine the right dose of AZD5335 when given with other drugs, potentially improving treatment for ovarian cancer.
What could go wrong
This is a very early Phase 1 study with only 24 people. It focuses on drug levels, not on curing cancer, and may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Batumi, 6010, Georgia

  • Research Site

    NOT_YET_RECRUITING

    Tbilisi, 0114, Georgia

  • Research Site

    NOT_YET_RECRUITING

    Tbilisi, 112, Georgia

  • Research Site

    RECRUITING

    Dublin, D07 R2WY, Ireland

  • Research Site

    RECRUITING

    Lisbon, 1250-068, Portugal

  • Research Site

    RECRUITING

    Barcelona, 08023, Spain

  • Research Site

    RECRUITING

    Logroño, 26006, Spain

  • Research Site

    RECRUITING

    Madrid, 28040, Spain

  • Research Site

    RECRUITING

    Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.